Bayer's Trasylol Increases Risk Of Death: Study

Law360, New York (June 2, 2008, 12:00 AM EDT) -- Just weeks after Bayer AG yanked the leftover stock of its blood-clotting drug Trasylol from the U.S. market, a newly published study has revealed that patients receiving the drug have a greatly increased risk of death.

The final results of the long-awaited study, published last Thursday in the New England Journal of Medicine, showed that Trasylol increases the risk of death by 54% while also greatly increasing the risk of other heart complications.

Bayer suspended sales of Trasylol in November at the urging of the U.S....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.